Evaluation the Relationship Between Myocardial Fibrosis and Left Ventricular Torsion Measured by Cardiac Magnetic Resonance Feature-tracking in Hypertrophic Cardiomyopathy Patients with Preserved Ejection Fraction

Overview

Journal Int J Cardiovasc Imaging

Publisher Springer

Specialty Radiology

Date 2024 Mar 6

PMID 38448705

Authors

Ying Zhong

Ce Li

Yang Yu

Yaqi Du

Yun Bai

Xinrui Wang

Xu Dai

Guoguang Fan

Guan Wang

Affiliations

Soon will be listed here.

Abstract

The relationship between left ventricular (LV) torsion and myocardial fibrosis (MF) in hypertrophic cardiomyopathy (HCM) patients with preserved ejection fraction was still not well understood. New developments in cardiac magnetic resonance (CMR) enable a much fuller assessment of cardiac characteristics. This study sought to assess the impact of HCM on myocardial function as assessed by LV torsion and its relationship with MF. HCM (n = 79) and healthy controls (n = 40) underwent CMR. According to whether there was late gadolinium enhancement (LGE), patients were divided into LGE group and LGE group. LV torsion and torsion rate were measured by CMR feature-tracking (CMR-FT). MF was quantitatively evaluated through LGE imaging. LGE was present in 44 patients (56%). Compared with healthy controls, torsion increased in the LGE group (P < 0.001). Compared with LGE group, torsion was higher in the LGE group (P < 0.001). There was no significant difference in torsion between LGE group and healthy controls. Correlation analysis showed that torsion was correlated with LGE% (r = - 0.443) and LGE mass (r = - 0.435) respectively. On multivariable logistic regression analysis, LV torsion was the only feature that was independently associated with the presence of LGE (OR 0.130; 95% CI 0.040 to 0.420, P = 0.01). The best torsion value associated with MF was 1.91 (sensitivity 60.0%, specificity 77.3%, AUC = 0.733). In HCM patients with preserved ejection fraction, CMR-FT derived LV torsion analysis holds promise for myocardial fibrosis detection.

References

Gersh B, Maron B, Bonow R, Dearani J, Fifer M, Link M . 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 124(24):2761-96. DOI: 10.1161/CIR.0b013e318223e230. View

Maron B, McKenna W, Danielson G, Kappenberger L, Kuhn H, Seidman C . American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the.... Eur Heart J. 2003; 24(21):1965-91. DOI: 10.1016/s0195-668x(03)00479-2. View

OHanlon R, Grasso A, Roughton M, Moon J, Clark S, Wage R . Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010; 56(11):867-74. DOI: 10.1016/j.jacc.2010.05.010. View

Chan R, Maron B, Olivotto I, Pencina M, Assenza G, Haas T . Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014; 130(6):484-95. DOI: 10.1161/CIRCULATIONAHA.113.007094. View

Bruder O, Wagner A, Jensen C, Schneider S, Ong P, Kispert E . Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010; 56(11):875-87. DOI: 10.1016/j.jacc.2010.05.007. View

Weng Z, Yao J, Chan R, He J, Yang X, Zhou Y . Prognostic Value of LGE-CMR in HCM: A Meta-Analysis. JACC Cardiovasc Imaging. 2016; 9(12):1392-1402. DOI: 10.1016/j.jcmg.2016.02.031. View

Mentias A, Raeisi-Giglou P, Smedira N, Feng K, Sato K, Wazni O . Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function. J Am Coll Cardiol. 2018; 72(8):857-870. DOI: 10.1016/j.jacc.2018.05.060. View

Galati G, Leone O, Pasquale F, Olivotto I, Biagini E, Grigioni F . Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy: A Clinical-Pathological Study of 30 Explanted Hearts. Circ Heart Fail. 2016; 9(9). DOI: 10.1161/CIRCHEARTFAILURE.116.003090. View

Moravsky G, Ofek E, Rakowski H, Butany J, Williams L, Ralph-Edwards A . Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging. 2013; 6(5):587-96. DOI: 10.1016/j.jcmg.2012.09.018. View

10.

Kuo P . Gadolinium-containing MRI contrast agents: important variations on a theme for NSF. J Am Coll Radiol. 2008; 5(1):29-35. DOI: 10.1016/j.jacr.2007.08.014. View

11.

Thomsen H . ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol. 2007; 17(10):2692-6. DOI: 10.1007/s00330-007-0744-5. View

12.

Arts T, Reneman R, Veenstra P . A model of the mechanics of the left ventricle. Ann Biomed Eng. 1979; 7(3-4):299-318. DOI: 10.1007/BF02364118. View

13.

Young A, Cowan B . Evaluation of left ventricular torsion by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012; 14:49. PMC: 3461493. DOI: 10.1186/1532-429X-14-49. View

14.

Ashwal A, Mugula S, Samanth J, Paramasivam G, Nayak K, Padmakumar R . Role of deformation imaging in left ventricular non-compaction and hypertrophic cardiomyopathy: an Indian perspective. Egypt Heart J. 2020; 72(1):6. PMC: 6975599. DOI: 10.1186/s43044-020-0041-z. View

15.

Liu S, Li Y, Zhao Y, Wang X, Wu Z, Gu X . The Combination of Feature Tracking and Late Gadolinium Enhancement for Identification Between Hypertrophic Cardiomyopathy and Hypertensive Heart Disease. Front Cardiovasc Med. 2022; 9:865615. PMC: 9130652. DOI: 10.3389/fcvm.2022.865615. View

16.

Shetty R, Samanth J, Nayak K, Sarang A, Thakkar A . Evaluation of subtle left ventricular systolic abnormalities in adult patients with hypertrophic cardiomyopathy. J Clin Diagn Res. 2015; 8(12):MC05-9. PMC: 4316285. DOI: 10.7860/JCDR/2014/10185.5287. View

17.

Russel I, Brouwer W, Germans T, Knaapen P, Marcus J, van der Velden J . Increased left ventricular torsion in hypertrophic cardiomyopathy mutation carriers with normal wall thickness. J Cardiovasc Magn Reson. 2011; 13:3. PMC: 3025877. DOI: 10.1186/1532-429X-13-3. View

18.

Ochs A, Johannes Riffel , Marco M Ochs , Arenja N, Fritz T, Galuschky C . Myocardial mechanics in dilated cardiomyopathy: prognostic value of left ventricular torsion and strain. J Cardiovasc Magn Reson. 2021; 23(1):136. PMC: 8638178. DOI: 10.1186/s12968-021-00829-x. View

19.

Kowallick J, Lamata P, Hussain S, Kutty S, Steinmetz M, Sohns J . Quantification of left ventricular torsion and diastolic recoil using cardiovascular magnetic resonance myocardial feature tracking. PLoS One. 2014; 9(10):e109164. PMC: 4186780. DOI: 10.1371/journal.pone.0109164. View

20.

Sengupta P, Narula J . Reclassifying heart failure: predominantly subendocardial, subepicardial, and transmural. Heart Fail Clin. 2008; 4(3):379-82. DOI: 10.1016/j.hfc.2008.03.013. View